Agenda
� 3:00-3:30 PM Networking, Registration & Tour
� 3:30-5:00 PM Expert Panel
� 5:00-6:30 PM Networking Reception

From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them.

Questions that will be raised include:
� What are the best approaches for identifying a good partner?
� What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A;?
� What about the rising of Big Pharma VC Funds?
� What are the strategies for attracting, securing and structuring strategic investments?
� How the Larger Bio-Companies� needs differ from VCs� needs?
� What are the key contract terms to be negotiated?
� What are the strategic reasoning behind different kinds partnerships?
� Effects on existing and potential future collaboration partners and other strategic decisions.
� Pros and cons of a small company partnering with a larger company.
� �Dos� and �don�ts� of managing these important relationships.

S. Edward Torres, Managing Director, Lilly Ventures
Mr. Torres is a Managing Director of Lilly Ventures, the venture capital arm of Eli Lilly and Company, and has over 18 years of experience in the pharmaceutical and venture capital businesses. He led the investments in, and currently serves as a director of, Cylene Pharmaceuticals, Serenex, Fluidigm and Trinity Biosystems and previously served as a director of Conforma Therapeutics (acquired by Biogen Idec) and Cabrellis Pharmaceuticals (acquired by Pharmion). Prior to his role in Lilly Ventures, Mr. Torres had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A;, business development and global marketing roles. He received a bachelors of arts from Creighton University and a master of business administration from the University of Michigan Business School, where he was a Consortium Fellow.

Suzy Jones, Senior Director, Business Development, Genentech, Inc.
Suzy Jones is Senior Director of Business Development at Genentech, Inc. As a member of the Business Development team, Suzy heads-up a group of licensing professionals responsible for building out Genentech�s pipleline outside of the area of Oncology. Her group is responsible for identifying new opportunities that will support the company�s short- and long-term strategic objectives and negotiating and structuring collaboration agreements to support the newly formed strategic alliances. Suzy�s career includes 18 years of biotech experience. She spent 7 years conducting basic Immunology Research evaluating the role of adhesion molecules in inflammation, 4 years in Product Development where she managed several pipeline products at various stages of their lifecycles, including Rituxan, Avastin, and Raptiva, and 7 years in business development overseeing Genentech�s licensing efforts in Immunology, Tissue Growth and Repair, New Therapeutic Areas and Technology Licensing.

Sara M. Hall, Founder, Director & Chief Executive Officer, Tacere Therapeutics, Inc.
Prior to founding Tacere, Sara was a Director and the Chief Executive Officer of Benitec Limited, an Australian Stock Exchanged-listed company developing RNAi-based therapeutics. Sara joined Benitec through its acquisition of Avocel Inc., one of the pioneering companies in the development of RNAi therapeutics. After creating a 9X return in 18 months for her investors in Avocel, Sara became the Chief Operating Officer and ultimately CEO of Benitec. Sara has a proven track record as a biotech entrepreneur, from conception through due diligence, license negotiation, staffing, facilities, marketing, funding, and M&A; and has held senior positions in R&D; as well as intellectual property and business development at Boehringer Ingelheim, Clontech/BD Biosciences, and B-Bridge International. Sara has been recognized for both her business and scientific innovations, including serving on the Scientific Advisory Board of Sigma-Aldrich and as the recipient of two R&D; 100 Awards. Sara holds BS and MS degrees in virology.

Mohan Iyer, Managing Director, Merchant Banking, Burrill & Company
Mr. Iyer brings to Burrill & Company a broad background in a range of functions including business development, strategic planning, marketing, product development, engineering and manufacturing. Prior to joining Burrill & Company, he was Executive VP of Corporate Development at diaDexus where he was responsible for sourcing and executing various types of transactions for a seven-year period, including discovery collaborations, in-licensing, out-licensing, manufacturing/supply contracts, and a spin-out. He has extensive experience in diagnostics, including alliances with major national reference laboratories. He also sourced and closed a therapeutic monoclonal antibody co-development agreement with Medarex. While at diaDexus, Mr. Iyer played a key role in two private financings totaling over $130mm, managed R&D; operations for a transition year, and headed the marketing launch of a novel cardiovascular diagnostic product. Prior to diaDexus, he was a healthcare consultant at The Wilkerson Group where he managed several strategic engagements across the pharmaceutical, biotech, diagnostics and medical device industries. Mr. Iyer began his biotech career as a biochemical process engineer at Genentech, where he spent 7 years in positions ranging from biopharmaceutical manufacturing to capital projects management. He holds a BS in Chemical Engineering (Tennessee), an MS in Biomedical Engineering (Duke), and an MBA (Yale).

David Summa, President & CEO, Acumen Pharmaceuticals
David Summa is currently the President and CEO of Acumen Pharmaceuticals, a pre-clinical drug development company that is developing the first effective therapeutics and diagnostics that prevent Alzheimer's disease. Prior to joining Acumen, Dave was the President and CEO of Mendel Biotechnology, a successful genomics company that was the first to functionally characterize all the transcription factors in arabidopsis thaliana. Mendel's traits now form the core of the Monsanto product pipeline. Before joining the ranks of Bay Area biotech entrepreneurs, Dave was a Vice President at Monsanto where he created Renessen, the joint venture between Cargill and Monsanto. Prior to joining Monsanto, Dave was a partner at McKinsey & Company, Inc. where he was the global leader of the Innovation Practice. Dave received his BS and MS from MIT in the department of Chemical Engineering.

Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate attorney in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings, and technology transactions. A representative list of Mr. Iyama's clients include CellPoint Dialogistic, Facebook, Greenplum, Laserscope, Micrus Endovascular and SquareOne. Mr. Iyama has also represented Benchmark Capital, De Novo Ventures, Kleiner Perkins Caufield & Byers, Maveron, Montreux Equity Partners, Telegraph Hill Partners in various investments. Prior to receiving his J.D. from Stanford Law School, Mr. Iyama received a M.S. and B.S in Biochemistry/Cell Biology from the University of California, San Diego. Mr. Iyama also performed extensive research at Genentech, Inc. and the NASA/Ames Research Center.